Blog
NETRF Announces $2.5 Million in Research to Advance the NETs
New grants to explore CAR-T, PRRT, a vaccine for NETs and other innovative approaches.
February 1, 2019
No Comments
New grants to explore CAR-T, PRRT, a vaccine for NETs and other innovative approaches.
Clarivate Analytics has released the most influential researcher list for 2018, which identifies exceptional researchers whose highly cited work is among the top 1% in their field around the world.
Early Research on Targeting Single Cancer Cells to Prevent Metastasis Despite the effectiveness of Peptide Receptor Radionuclide Therapy (PRRT) to prolong survival of those with
Antibody-drug conjugate aims to combine the benefits of targeted therapy and chemotherapy Renata Jaskula-Sztul, PhD, Assistant Professor of Surgical Oncology at the University of Alabama
Immunotherapy has been called one of the most significant advances in cancer in decades. While this approach may work in some cancers, it is unclear
Immunotherapy has been called one of the most significant advances in cancer in decades. While this approach may work in some cancers, it is unclear
New Potential NET Treatment under Investigation It is hard for doctors to know which patients will respond to which therapies. New approaches in personalized medicine
Antibody-drug conjugate aims to combine the benefits of targeted therapy and chemotherapy Renata Jaskula-Sztul, PhD, Assistant Professor of Surgical Oncology at the University of Alabama
If you are having surgery for a NET tumor, consider donating some of your tumor tissue to help research. The Neuroendocrine Tumor Research Foundation is
The Neuroendocrine Tumor Research Foundation (NETRF) has invested more than $1.5 million in advancing a precision form of radiation therapy for NETs called Peptide Receptor